Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by ... a proven management team including former AveXis leadership, Jaguar Gene Therapy has the expertise to accelerate the development, manufacturing and commercialization of novel gene therapy treatments. The company is supported by a group of visionary investors, including Deerfield Management, Eli Lilly and Company, ARCH Venture Partners, Goldman Sachs and Nolan Capital. Jaguar’s current pipeline utilizes the proven and well-characterized AAV9 vector to target diseases in patient populations with large unmet need, including galactosemia, genetic causes of autism spectrum disorder and Type 1 diabetes. Additionally, Axovia Therapeutics, a majority-owned subsidiary of Jaguar Gene Therapy that is focused on creating transformative therapies for ciliopathies, is advancing a gene therapy treatment for BBS1, a subset of Bardet-Biedl syndrome (BBS). read more